| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,
,¶,
* Institut National de la Santé et de la Recherche Médicale Unité 543, Immunologie A, Assistance Publique-Hôpitaux de Paris (AP-HP) Hôpital Pitié-Salpêtrière, Paris, France;
Internal Medicine Department, AP-HP Hôpital Pitié-Salpêtrière, Paris, France;
Université Pierre et Marie Curie (Paris VI), Paris, France;
Institut National de la Santé et de la Recherche Médicale Unité 255, Centre de Recherches Biomédicales des Cordeliers, Paris, France; and
¶ Anatomopathology Department, AP-HP Hôpital Européen Georges Pompidou, Paris, France
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
-producing Th3 cells (4). The second type of regulatory T cell is the naturally occurring, or innate, regulatory T cell (Treg),4 characterized by constitutive expression of CD25 (1). These cells mediate their suppressive effect through a contact-dependent, but as yet undefined, mechanism to inhibit autologous CD25– T cell proliferation and Th1 cytokine secretion, and to modulate the Ag-presenting capacity of dendritic cells (5, 6, 7, 8). Since their first description in humans (9, 10, 11, 12, 13, 14, 15, 16), Tregs have been the focus of intense research efforts, notably in the context of autoimmune diseases (17, 18, 19, 20, 21, 22, 23, 24). It is now clear that the forkhead transcription factor Foxp3 acts as a critical regulator in the development and function of Tregs (25, 26, 27, 28, 29). The best evidence for Tregs as being key in the control of self-tolerance in humans therefore comes from the causal association between the rapidly fatal immune dysregulation, polyendocrinopathy, X-linked syndrome, and mutations in FOXP3 (30, 31). In chronically ill patients, a deficiency in Treg-suppressive function has been observed in vitro and has been suggested to influence the pathogenesis of diabetes (20), multiple sclerosis (21), rheumatoid arthritis (22), type II autoimmune polyendocrinopathy (23), and psoriasis (24). In the latter studies, the underlying defect accounting for the inability of the patient’s Tregs to suppress lymphocyte proliferation and/or cytokine production could not be identified. Other authors reported that Tregs isolated from patients affected by various types of rheumatoid disorders (rheumatoid arthritis, spondyloarthropathies, and juvenile idiopathic arthritis) presented no apparent functional deficiency (32, 33, 34). Comparison between these studies is complicated by the fact that a means of defining phenotypically Tregs in humans is still lacking. Indeed, live cells cannot be purified on the basis of their Foxp3 expression. Tregs have been shown in humans to be mainly confined to the CD25bright subset of CD4+ cells (13) and were therefore purified according to these criteria (17, 18, 19, 20, 21, 22, 23, 24, 32, 33, 34). CD25 being also expressed on non-Treg subsets, it is possible that the proportion of actual Tregs purified along with other CD25+ cells would vary between laboratories and/or disease stages, accounting for the apparent discrepancies found in the literature.
Mice depleted in CD4+CD25+ T cells develop a multisystemic autoimmune disease, including gastritis, oophoritis, arthritis, and thyroiditis. Interestingly, some animals also developed glomerulonephritis and activated the production of anti-dsDNA Abs (1). The latter features are obviously reminiscent of systemic lupus erythematosus (SLE), a condition characterized by a multisystemic autoimmune involvement and by the targeting of typical disease-associated Ags such as dsDNA. These findings led us and others (35, 36, 37) to envisage that Tregs may play an important role in the pathophysiology of SLE.
Previous studies in SLE patients (35, 36) argued in favor of a decrease in circulating Treg numbers during disease flares, which was suggested to reflect their reallocation to lymphoid organs or disease-affected tissues. It was also reported that the immunosuppressive activity of the latter cells was impaired in patients presenting with active disease (37).
In this study, contrary to what was previously proposed, we show that SLE CD4+CD25bright T cells are as potent immunoregulators as corresponding control cells. However, levels of circulating Tregs cells are indeed reduced during SLE flares. The contraction of the circulating Treg subset does not seem to reflect its tissue reallocation, as Foxp3+ cells do not accumulate in disease-involved organs or in lymphoid tissues. Finally, a mechanism leading to Treg depletion is proposed as we show that SLE Tregs are more sensitive to Fas-mediated apoptosis than control Tregs (38). Our results argue that inappropriate induction of Treg apoptosis is relevant to SLE pathogenesis.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
One hundred and seven consecutive adult patients (98 women and 9 men, mean age 35.8 ± 14.5 years, range 15–76 years) with a diagnosis of SLE according to the American College of Rheumatology criteria (39, 40) were included in the study. All SLE patients were referred to the internal medicine department at the Hospital Pitié-Salpêtrière (Paris, France). The SLE patients were divided into two groups according to their SLE disease activity index (SLEDAI), a validated index of SLE activity (41), with one group comprising subjects with inactive SLE (SLEDAI 
3, n = 62, mean age 39.5 ± 15.6 years, 56 women and 6 men, mean lymphocyte number 1395 ± 657/mm3) and a second group comprising patients with active SLE (SLEDAI >3, n = 45, mean age 32.5 ± 11.8 years, 42 women and 3 men, mean lymphocyte number 1107 ± 569/mm3). Blood samples from 82 age- and sex-matched healthy donors (mean lymphocyte number 2117 ± 699/mm3) were obtained from Etablissement Français du Sang (Hôpital Pitié-Salpêtrière). Treatment regimens in the active SLE group were as follows: hydroxychloroquine (HCQ) alone (n = 7), HCQ + prednisone (n = 22), HCQ + prednisone + methotrexate (n = 3), HCQ + prednisone + cyclophosphamide (n = 2). Eleven active patients were untreated at the time of analysis (Table I). Two control autoimmune disease groups consisted of 16 primary Sjögren syndrome (pSS; mean age 50 ± 12.7 years, 15 women and 1 man) and 21 inflammatory myopathy (IM; mean age 48.2 ± 15.5 years, 15 women and 6 men) patients. Clinical features fulfilled Bohan and Peter criteria in IM patients (42) and criteria of the European Community Study group in pSS patients (43).
|
The study was performed according to the Helsinki declaration. The study protocol was reviewed and approved by the local ethics committee.
Cell isolation and flow cytometry
All blood samples were collected and processed within 2 h. PBMC were purified on Ficoll gradients (Eurobio). LN and kidney samples were disrupted immediately after surgery or biopsy using a scalpel and gently teased in culture medium to obtain a mononuclear cell suspension. Control and active SLE sera were collected and frozen at –20°C until used. Sera were heat inactivated at 56°C for 30 min and centrifuged before use.
Cells were stained with anti-CD4 PerCP or anti-CD4 FITC, anti-CD25 PE or anti-CD25 allophycocyanin, anti-CD95 allophycocyanin mAbs (BD Pharmingen), and anti-CCR4 PE (R&D Systems). For intracellular detection of CTLA-4, surface staining was first performed; cells were then fixed and permeabilized using Cytofix/Cytoperm (BD Biosciences) and incubated with anti-CD152 PE (BD Biosciences). Samples were analyzed on FACSCalibur equipment (BD Biosciences). A total of 500,000 events was acquired and data were analyzed with WinMDI 2.8 (freeware; J. Trotter; 
http://facs.scripps.edu/software.html
). CD4+ T cells were FACS sorted according to their CD25 expression level (FACSVantage DIVA; BD Biosciences). CD25bright gate was adjusted to contain CD4+ T cells that express CD25 more brightly than CD4–CD25+ cells.
Proliferation assays and cytokine detection
Varying numbers of sorted CD4+CD25bright T cells were cocultured with 2.5 103 autologous CD4+CD25– responder T cells and 2.5 104 allogeneic T cell-depleted PBMCs (irradiated at 5000 rad) in 96 U-bottom well plates coated with 0.5 µg/ml OKT3 (Orthoclone; Orthobiotech). The medium used for culture was based on RPMI 1640 (Invitrogen Life Technologies) supplemented with 10% of FCS (Boehringer Mannheim), 2 mM L-glutamine, 1 mM sodium pyruvate, 1% nonessential amino acids, 100 U/ml penicillin, and 100 µg/ml streptomycin (all from Invitrogen Life Technologies). On day 5, 1 µCi of [3H]thymidine (Valeant Pharmaceuticals) was added for the final 16 h of culture. Proliferation was determined by scintillation counting on day 6 (PerkinElmer Wallac). IL-2, IL-4, IL-5, IL-10, IFN-
, and TNF-
levels were measured in supernatants of cell cultures collected on day 5 using a cytometric bead array kit (BD Biosciences), according to the manufacturer’s instructions. None of the patients tested for proliferation and cytokine production was on steroids at the time of analysis.
Detection of Foxp3+ T cells in LN
Frozen LN tissues obtained from SLE patients (n = 5) and control LN (n = 2) were cut 5 µm thick, fixed in acetone, and blocked for endogenous biotin (Vector Laboratories). Biopsy samples were stained with polyclonal goat anti-human Foxp3 (ab2481, 500 µg/ml, IgG, 1/100 dilution; Abcam) and mouse anti-human CD4 (MT310, IgG1, 100 µg/ml, 1/100 dilution; DakoCytomation), followed by FITC-conjugated rat anti-mouse (145-095-166, IgG, 1 mg/ml, 1/100 dilution; Jackson ImmunoResearch Laboratories) and biotinylated rabbit anti-goat (E0466, 1 mg/ml, 1/400 dilution; DakoCytomation), followed by cyanine 3-conjugated streptavidin (PA43001, 1 mg/ml, 1/300 dilution; Amersham Biosciences). Irrelevant isotype-matched Abs (DakoCytomation) were also used as primary Abs in control experiments. Fluorescent images of mounted sections were acquired with an epifluorescent microscope (Axioplan 2; Zeiss) and analyzed with FluoUp image analysis system software (Explora Nova). Density of Foxp3+ T cells was determined as the number of positive cells per mm2 in relevant LN areas (B cell areas of the LN sections were excluded). The mean size of a single analyzed area was 6.5 x 105 µm2. Data were collected in three separate areas per section and then averaged. Each biopsy was assessed twice, with result variations always <10%.
Real-time Foxp3 PCR
Real-time PCR was performed with a TaqMan assay on an ABI 7700 system (Applied Biosystems). Total RNA extracted from kidney tissues of patients with lupus nephropathy or healthy controls (graft donors) and from FACS sorted T cells was immediately reverse transcribed in a 50 µl reaction volume (ProSTAR First Strand; Stratagene), according to the manufacturer’s instructions. FOXP3 and hypoxanthine phosphoribosyltransferase-1 (HPRT-1) Assays-on-Demand gene expression probes (Hs 00203958 and 99999909, respectively; Applied Biosystems) were used. In each reaction, HPRT-1 was amplified as a housekeeping gene to calculate a standard curve and to correct for variations in target sample quantities. Relative copy numbers were calculated for each sample from the standard curve after normalization to HPRT-1 by the instrument software.
Fas-induced apoptosis assay
Freshly drawn PBMC (1 x 106) stained with anti-CD4 FITC and anti-CD25 PE were incubated for 12 h in 5 µg/ml plate-bound OKT3 96-well plate, then incubated with medium only or with 5 µg/ml anti-Fas (DX2 clone; BD Biosciences) or with 1% control or active SLE serum for 1 h. Cells were washed with cold PBS. Anti-Fas-induced apoptosis was measured using annexin V allophycocyanin (BD Biosciences), according to the manufacturer’s instructions. The 7-aminoactinomycin D staining (BD Biosciences) was used to exclude dead cells. Cells were analyzed on FACSCalibur equipment.
Statistical analysis
Comparisons between active and inactive SLE patients and control subjects were made using the nonparametric Mann-Whitney U test. Comparisons of the rate of circulating CD25brightCD4+ T cells during the evolution of the disease were made using the paired t test. Similar tests were used in apoptosis assays to compare annexin V+ cell proportions. Correlations were determined by Spearman’s ranking. Values of p < 0.05 were considered significant.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
At this time, a clear-cut phenotypic definition of Tregs remains unestablished. Tregs are usually distinguished among CD4+ T cells by their high expression of CD25 and their ability to strongly suppress proliferation of autologous naive CD25–CD4+ T cells in a contact-dependent manner (13, 44). However, there are no standard criteria to set the minimal CD25 expression level that would define a pure Treg population. We have therefore attempted to base our work on a strictly functional definition of this subpopulation to study its behavior in lupus patients. We FACS sorted CD4+ T cells above various thresholds of CD25 expression and tested each subset for its ability to suppress autologous T cell proliferation and cytokine secretion. As shown, subtle contamination of the CD4+CD25bright subpopulation by CD4+CD25low cells greatly impacts analytic evaluation of immunosuppressive function (Fig. 1a). According to our comparative functional assessment of CD4+CD25+ fractions of increasing size, a minimal CD25 threshold for Treg definition corresponds in active patients and controls to the highest expression level of the same marker in CD4– T cells (Fig. 1a).
|
Treg-suppressive function is not qualitatively impaired in SLE
CD4+CD25bright T cells from healthy controls (n = 9), active SLE patients (n = 4), and inactive patients (n = 4) were FACS sorted, as described above, and tested for their ability to suppress autologous T cell proliferation and cytokine secretion. In all cases, purified cells inhibited at least 95% of baseline proliferation of autologous T lymphocytes (Fig. 1c) and abolished Th1 and Th2 cytokine secretion (Fig. 1d).
Contraction of the circulating Treg subset is correlated to disease activity
The percentage of circulating CD4+CD25bright T cells among CD4+ T cells was measured in healthy controls and SLE patients using cytofluorometry. As shown in Fig. 2a, a significant decrease in the mean value for patients with active SLE (0.57 ± 0.24%, n = 45, p < 0.0001) is evidenced when this group is compared with healthy controls (1.29 ± 0.38%, n = 82) or with inactive patients (1.22 ± 0.67%, n = 62, p < 0.0001). Within the active group, we found no significant difference in terms of Treg proportion between treated (n = 34) and untreated patients (n = 11; data not shown). No significant difference was observed between inactive SLE and healthy controls (p = 0.07). (See Fig. 1a for a representative staining pattern.) Off note, the decrease in Treg proportion among CD4+ T cells that we observe indeed corresponds to a significant decrease in absolute numbers of such cells in active SLE patients. Treg absolute numbers are significantly decreased in active SLE patients when compared with controls (2.97 ± 2.1 cells/mm3 vs 13.51 ± 5.3, p < 0.0001) or inactive SLE patients (7.33 ± 5.7 cells/mm3, p < 0.001). We also found that the absolute number of Tregs in inactive SLE patients was lower than in controls (p < 0.0001). Because mild lymphopenia can often persist in inactive SLE (mean lymphocyte counts in our inactive patients: 1395 ± 657/mm3 vs 2117 ± 699/mm3 in controls), the absolute numbers of Tregs and of cells of other CD4 subsets are reduced in a parallel way, leading to a normal Treg proportion in inactive patients.
|
We next questioned whether Treg subset size would vary within the same individual in relation to disease status. In 10 individuals tested longitudinally, there was a significant increase in the latter subset size, which returned to control levels upon resolution of the flare (0.39 ± 0.20% vs 1.28 ± 0.39%, p = 0.0005; Fig. 2b). Moreover, we found a strong negative correlation between Treg subset size and the SLEDAI (p = 0.0002, p = –0.58; Fig. 2c).
These results argue strongly in favor of a Treg involvement in the disease process.
Tregs do not accumulate in SLE-involved organs or in lymphoid tissues
One possible explanation for the observed reduction in circulating Treg numbers during SLE flares is recruitment of these cells to lymphoid tissues and/or compartments with disease activity.
We first evaluated whether the decrease in circulating Tregs could be correlated with signs related to a particular organ involvement. We compared the proportion of CD4+CD25bright cells in active SLE patients with kidney disease and in active SLE patients without kidney involvement. There is no significant difference between these two groups (kidney disease group, 0.533 ± 0.213%, n = 23 and no kidney disease group, 0.61 ± 0.267, n = 22, p = 0.335). We also compared the proportion of Tregs in active SLE patients with and without skin involvement. Neither was there a significant difference between the later (skin disease group, 0.581 ± 0.232%, n = 17 and no skin disease group, 0.565 ± 0.251, n = 28, p = 0.66). Finally, we compared the proportion of Tregs in active SLE patients with and without arthritis. Again, we did not find any statistically significant difference between these two groups (arthritis group, 0.586 ± 0.256, n = 21 and no arthritis group, 0.559 ± 0.233, n = 24, p = 0.91).
We next attempted to directly localize Tregs in tissues using sensitive techniques. Foxp3 is a transcription factor critical to the development of Tregs (25, 26) and to date considered the best marker available to define innate Tregs. We used bicolor microscopic analysis to localize CD4+Foxp3+ cells in tissues. We show that there are significantly less Tregs in SLE LN (n = 5) than in control LN (9.63 ± 3.74 cells/square millimeter vs 94.00 ± 39.20 cells/square millimeter, n = 2; p < 0.0001, Fig. 3a). We also studied kidney biopsies obtained from patients with lupus nephritis. Using real-time PCR, we found that FOXP3 expression is not significantly increased in SLE kidneys (n = 5, Fig. 3b) compared with control kidney tissue (n = 1, Fig. 3b). Finally, FACS analysis of cells isolated from a spleen removed for refractory lupus thrombocytopenia evidenced only 0.63% of CD4+CD25bright T cells among CD4+ T cell splenocytes (data not shown).
|
Tregs of SLE patients are sensitive to Fas-dependent apoptosis
We hypothesized that a dysfunction in the control of Treg survival could lead to their depletion in vivo. It was shown previously that Fas (CD95) is constitutively expressed on Tregs (48). As shown above (Fig. 1b), we confirmed that SLE CD4+CD25bright T cells also express high levels of Fas. We assessed the susceptibility of Tregs from active or inactive SLE patients and healthy controls to Fas-mediated apoptosis. Total PBMCs were labeled with anti-CD4 and anti-CD25 Abs and incubated for a short time period (12 h) in the presence of immobilized anti-CD3 Abs. Apoptosis was then induced by adding an anti-Fas mAb to the cultures for 1 h. Cells were then washed and CD4+CD25bright T cells monitored for annexin V binding. We determined in preliminary experiments that, although fluorescence intensities declined, CD4+CD25bright T cells remain detectable and that CD4+CD25bright/CD4+CD25– ratios remain stable up until 16 h in culture medium (data not shown). In healthy controls, Tregs activated by anti-CD3 are less prone to Fas-dependent apoptosis than CD4+CD25– T cells (2.04 ± 0.4% vs 5.05 ± 0.4%, n = 24, p = 0.0003, Fig. 4). In contrast, SLE Tregs are more susceptible to Fas-mediated apoptosis than autologous CD4+CD25– T cells (6.52 ± 1.15% vs 3.56 ± 0.50%, p = 0.013, n = 10). Patients with inactive (n = 5) or active disease (n = 5) were both included in the test. Tregs of SLE patients are also more prone to Fas-mediated apoptosis than those of controls (6.52 ± 1.15% vs 2.04 ± 0.4%, p = 0.0005). In the absence of Fas stimulation, SLE Tregs do not engage significantly faster in activation-induced apoptosis than autologous CD4+CD25– T cells.
|
These results suggest that exacerbated Fas-mediated apoptosis susceptibility could lead to Treg depletion during SLE flares independently of a soluble factor.
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
Although the probable implication of Tregs in diverse pathologies has generated enormous interest (17, 18, 19, 20, 21, 22, 23, 24, 32, 33, 34), it remains difficult to purify them in humans, and even more so in leukopenic subjects such as SLE patients. Tregs are relatively easy to characterize in mice given that they correspond to the CD4+ T lymphocytes that constitutively express CD25. However, in humans, a large fraction of CD25+ cells are activated cells, and the majority of these are nonregulatory. Previous publications have reported the existence of quantitative anomalies (35, 36) within the Treg subpopulation over the course of SLE. These studies could only give rise to speculative conclusions, as they were based on peripheral blood phenotypic analysis, omitting functional assays and the study of other tissues. Another group reported that Tregs would be functionally impaired during SLE flares (37). The latter study used for reference surprisingly elevated numbers of Tregs in control subjects (up to 10% of CD4+ T cells), raising the possibility that the studied subsets could have been highly contaminated with CD25+ non-Tregs. In the adult, the Treg subset represents a mere 1.5% of the total CD4+ T lymphocyte population (13). Any study using for reference significantly more elevated numbers (20, 23, 24, 50) should be interpreted cautiously. It is shown in this study how Tregs could appear poorly functional in vitro if they are contaminated by CD4+CD25low lymphocytes. Therefore, if Treg purification is not as stringent as possible, the latter can be erroneously evaluated as being less functional. For the purposes of this study, analysis and sorting gates were defined to select only those cells that express CD25 most strongly. In control experiments, we used a single cell PCR approach to calculate precisely the fraction of Foxp3+ cells present among cells sorted according to criteria presented in this work (Fig. 1). Although virtually no CD4+CD25– cells expressed Foxp3, we determined by this approach that, on average, 86.5% of the sorted CD4+CD25bright cells were Foxp3+ (M. Miyara, Z. Amoura, and G. Gorochov, submitted for publication).
The hallmark of SLE is the production of anti-dsDNA Abs (51). Anti-dsDNA are found not only in the serum, but also in the diseased kidneys of SLE patients, suggesting a pathogenic role for these autoantibodies. Although there is now ample evidence that Tregs can regulate T cell-mediated responses, their role on the humoral response has been less explored. In a recent study (52), it was shown that a depletion or a lack of recruitment of Tregs to B cells and APCs resulted in a deregulated humoral response. A direct role of Tregs on B cells was evidenced in the same study because the authors further showed that Tregs can suppress LPS-induced B cell activation. More recently, it was shown in a mouse model that the anergy of anti-dsDNA B cells is reverted when T cell help is provided in the absence of Tregs (53). In light of these studies, our own data strongly suggest that the loss of Tregs during SLE flares could contribute to a lack of control on autoreactive B cells and therefore to the pathogenesis of SLE. Our findings are also in good agreement with the initial description of Sakaguchi et al. (1), in which mice depleted in CD25+CD4+ T cells developed multisystemic autoimmune features, including arthritis, glomerulonephritis, and anti-dsDNA Abs. Finally, it is proposed that depleting Tregs would represent a potential strategy for treating human cancers (45, 54, 55). Our data indirectly support this assertion, but also indicate that such potential therapies might be at the origin of adverse autoimmune side effects.
The specificity of Tregs remains unknown, but it is probable that they express TCRs with relatively high affinity for self Ags (56). SLE has been shown in numerous studies to be associated with reduced elimination of apoptotic cells (57, 58). It is proposed that dysfunction of rapid dead cell clearance leads to a superexposure of self Ags and to the expansion of a subpopulation of self-directed effector cells, the resulting imbalance ultimately leading to a loss of immune tolerance. To check the expansion of self-directed effector cells, it appears important that the immune system could maintain, or if necessary, amplify the level of the Treg subpopulation. Over the course of a graft-vs-host reaction, for example, patients appear capable of amplifying their Treg subpopulation in an appropriate manner (59). In the case of SLE, in contrast, the homeostatic control mechanisms of the Treg population appear to be profoundly perturbed.
We have attempted to explore at least two mechanisms that could affect Treg survival in SLE patients. We found no evidence for the presence of autoantibodies that would directly target Tregs, and therefore focused on the study of Tregs’ programmed cell death. Murine Tregs are relatively resistant to apoptosis (38). DNA array analyses identified in this subset a moderate up-regulation of several genes linked to cell survival (60) that could explain this behavior. In agreement with our own data, Taams et al. (10) reported that although human Tregs expressed high amounts of CD95, they were not particularly susceptible to CD95-mediated activation-induced cell death. The same authors reported that Tregs were more sensitive to cytokine deprivation-induced cell death (10), but this result was not confirmed by others (23). In this study, to avoid introducing bias such as cell proliferation and cell lysis, we only monitored early apoptotic events taking place after 13 h of culture (only 1 h in the presence of anti-Fas). We confirm that control human Tregs are not more prone to CD95-mediated activation-induced cell death than CD25+CD4+ T cells. In contrast, we show that lupus Tregs are hypersensitive to Fas-mediated cell death. We propose, therefore, that Tregs would be eliminated in vivo via inappropriate induction of apoptosis following massive exposure to self Ags arising during the course of lupus flares.
It is impossible to conclude at present whether the observed global depletion of Tregs is in fact the cause or consequence of the flare. In either case, this depletion could only exacerbate the extent of tissue damage. It would be of interest to determine whether the Tregs isolated from lupus patients express abnormal levels of the antiapoptotic factors already described (60). It would be equally interesting to determine whether this abnormal propensity for Fas-induced apoptosis can be reversed after in vivo expansion. Such manipulations could very well offer new therapeutic perspectives for the management of patients suffering from SLE (61).
We have previously described that active sarcoidosis (M. Miyara, Z. Amoura, and G. Gorochov, submitted for publication) is associated with a very significant Treg expansion, not only in blood, but also in involved organs. In this study, we conclude that the same subset is globally depleted during lupus flares. It is interesting to note that these two clinical entities, presenting with opposite immunoregulatory features (anergy vs systemic autoimmunity), rarely occur together (62).
|
Acknowledgments |
|---|
|
Disclosures |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
|
Footnotes |
|---|
1 This work was supported by grants from Institut National de la Santé et de la Recherche Médicale and Association Lupus France. M.M. was the recipient of a Fondation Line Pomaret Delalande price hosted by Fondation pour la Recherche Médicale, Paris. 
2 C.P. and C.B. contributed equally to this work.
3 Address correspondence and reprint requests to Dr. Guy Gorochov, Institut National de la Santé et de la Recherche Médicale Unité 543, Centre d’Etudes et de Recherches en Virologie et Immunologie, Hôpital Pitié-Salpêtrière, 83 boulevard de L’Hôpital, 75013, Paris, France. E-mail address: guy.gorochov{at}psl.aphp.fr
4 Abbreviations used in this paper: Treg, naturally occurring regulatory T cell; HCQ, hydroxychloroquine; HPRT, hypoxanthine phosphoribosyltransferase; IM, inflammatory myopathy; LN, lymph node; pSS, primary Sjögren syndrome; SLE, systemic lupus erythematosus; SLEDAI, SLE disease activity index.
Received for publication June 6, 2005. Accepted for publication October 5, 2005.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresReferences |
|---|
-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155: 1151-1164. [Abstract]-secreting Th3 regulatory cells. Immunol. Rev. 182: 207-214. [Medline] therapy. J. Exp. Med. 200: 277-285. -induced, CD8+ T-cell-dependent immune defense of B16 melanoma. Cancer Res. 61: 8643-8646. This article has been cited by other articles:
|
|
 |
|
  E. Tsantikos, C. Quilici, K. W. Harder, B. Wang, H.-J. Zhu, G. P. Anderson, D. M. Tarlinton, and M. L. Hibbs Perturbation of the CD4 T Cell Compartment and Expansion of Regulatory T Cells in Autoimmune-Prone Lyn-Deficient Mice J. Immunol., August 15, 2009; 183(4): 2484 - 2494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Wang, F. M.-M. Lai, L.-S. Tam, E. K.-M. Li, B. C.-H. Kwan, K.-M. Chow, P. K.-T. Li, and C.-C. Szeto Urinary FOXP3 mRNA in patients with lupus nephritis--relation with disease activity and treatment response Rheumatology, July 1, 2009; 48(7): 755 - 760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Kotsianidis, E. Nakou, I. Bouchliou, A. Tzouvelekis, E. Spanoudakis, P. Steiropoulos, I. Sotiriou, V. Aidinis, D. Margaritis, C. Tsatalas, et al. Global Impairment of CD4+CD25+FOXP3+ Regulatory T Cells in Idiopathic Pulmonary Fibrosis Am. J. Respir. Crit. Care Med., June 15, 2009; 179(12): 1121 - 1130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K Anam, M Amare, S Naik, K. Szabo, and T. Davis Severe tissue trauma triggers the autoimmune state systemic lupus erythematosus in the MRL/++ lupus-prone mouse Lupus, April 1, 2009; 18(4): 318 - 331. [Abstract] [PDF]
|
|
|
|
|
|
M. Bonelli, A. Savitskaya, C.-W. Steiner, E. Rath, J. S. Smolen, and C. Scheinecker Phenotypic and Functional Analysis of CD4+CD25-Foxp3+ T Cells in Patients with Systemic Lupus Erythematosus J. Immunol., February 1, 2009; 182(3): 1689 - 1695. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kaplan, L Woodworth, K Smith, J Coco, A Vitsky, and J. McPherson Therapeutic benefit of treatment with anti-thymocyte globulin and latent TGF-{beta}1 in the MRL/lpr lupus mouse model Lupus, September 1, 2008; 17(9): 822 - 831. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Bonelli, A. Savitskaya, K. von Dalwigk, C. W. Steiner, D. Aletaha, J. S. Smolen, and C. Scheinecker Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE) Int. Immunol., July 1, 2008; 20(7): 861 - 868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B Zhang, X Zhang, F L Tang, L P Zhu, Y Liu, and P E Lipsky Clinical significance of increased CD4+CD25-Foxp3+ T cells in patients with new-onset systemic lupus erythematosus Ann Rheum Dis, July 1, 2008; 67(7): 1037 - 1040. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-Y. Lee, Y.-K. Hong, H.-J. Yun, Y.-M. Kim, J.-R. Kim, and W.-H. Yoo Altered frequency and migration capacity of CD4+CD25+ regulatory T cells in systemic lupus erythematosus Rheumatology, June 1, 2008; 47(6): 789 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Kuhn and M Bijl Pathogenesis of cutaneous lupus erythematosus Lupus, May 1, 2008; 17(5): 389 - 393. [Abstract] [PDF]
|
|
|
|
|
|
A La Cava T-regulatory cells in systemic lupus erythematosus Lupus, May 1, 2008; 17(5): 421 - 425. [Abstract] [PDF]
|
|
|
|
|
|
M Bonelli, K von Dalwigk, A Savitskaya, J S Smolen, and C Scheinecker Foxp3 expression in CD4+ T cells of patients with systemic lupus erythematosus: a comparative phenotypic analysis Ann Rheum Dis, May 1, 2008; 67(5): 664 - 671. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Vargas-Rojas, J. Crispin, Y Richaud-Patin, and J Alcocer-Varela Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance Lupus, April 1, 2008; 17(4): 289 - 294. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Tritt, E. Sgouroudis, E. d'Hennezel, A. Albanese, and C. A. Piccirillo Functional Waning of Naturally Occurring CD4+ Regulatory T-Cells Contributes to the Onset of Autoimmune Diabetes Diabetes, January 1, 2008; 57(1): 113 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Cuda, S. Wan, E. S. Sobel, B. P. Croker, and L. Morel Murine Lupus Susceptibility Locus Sle1a Controls Regulatory T Cell Number and Function through Multiple Mechanisms J. Immunol., December 1, 2007; 179(11): 7439 - 7447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. E. Solomou, K. Rezvani, S. Mielke, D. Malide, K. Keyvanfar, V. Visconte, S. Kajigaya, A. J. Barrett, and N. S. Young Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia Blood, September 1, 2007; 110(5): 1603 - 1606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Barath, M. Aleksza, T. Tarr, S. Sipka, G. Szegedi, and E. Kiss Measurement of natural (CD4+CD25high) and inducible (CD4+IL-10+) regulatory T cells in patients with systemic lupus erythematosus Lupus, July 1, 2007; 16(7): 489 - 496. [Abstract] [PDF]
|
|
|
|
|
|
S. G. Zheng, J. Wang, P. Wang, J. D. Gray, and D. A. Horwitz IL-2 Is Essential for TGF-beta to Convert Naive CD4+CD25- Cells to CD25+Foxp3+ Regulatory T Cells and for Expansion of These Cells J. Immunol., February 15, 2007; 178(4): 2018 - 2027. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Valencia, C. Yarboro, G. Illei, and P. E. Lipsky Deficient CD4+CD25high T Regulatory Cell Function in Patients with Active Systemic Lupus Erythematosus J. Immunol., February 15, 2007; 178(4): 2579 - 2588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. C. Kyttaris, Y. Wang, Y.-T. Juang, A. Weinstein, and G. C. Tsokos Increased Levels of NF-ATc2 Differentially Regulate CD154 and IL-2 Genes in T Cells from Patients with Systemic Lupus Erythematosus J. Immunol., February 1, 2007; 178(3): 1960 - 1966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wan, C. Xia, and L. Morel IL-6 Produced by Dendritic Cells from Lupus-Prone Mice Inhibits CD4+CD25+ T Cell Regulatory Functions J. Immunol., January 1, 2007; 178(1): 271 - 279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Fritzsching, N. Oberle, E. Pauly, R. Geffers, J. Buer, J. Poschl, P. Krammer, O. Linderkamp, and E. Suri-Payer Naive regulatory T cells: a novel subpopulation defined by resistance toward CD95L-mediated cell death Blood, November 15, 2006; 108(10): 3371 - 3378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kuhn, P. H. Krammer, and V. Kolb-Bachofen Pathophysiology of cutaneous lupus erythematosus -- novel aspects Rheumatology, October 1, 2006; 45(suppl_3): iii14 - iii16. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Cesana, S. Kim-Schulze, and H. L. Kaufman In Reply J. Clin. Oncol., July 10, 2006; 24(20): e35 - e36. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
) or in the presence of different proportions of CD4+CD25bright autologous T cells (CD25bright:25– ratios are indicated). As shown, nine healthy controls, four active SLE patients, and four inactive SLE were tested for natural Treg activity. d, CD4+CD25bright cells from a representative control (left, n = 9) and from a representative active patient (right, n = 4) completely block secretion of IL-2, IL-5, IFN-
